Severe sunitinib-induced myelosuppression in a patient with a CYP 3A4 polymorphism

CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma

(2015) Meta H.M. Diekstra et al.   EUROPEAN UROLOGY

Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662

(2014) M H M Diekstra et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity

(2013) A.-J. M. de Graan et al.   CLINICAL CANCER RESEARCH

CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin

(2013) Laure Elens et al.   PHARMACOGENOMICS

Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib

(2010) A. A. M. van der Veldt et al.   CLINICAL CANCER RESEARCH

Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

(2010) D Wang et al.   PHARMACOGENOMICS JOURNAL

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors

(2009) R Kumar et al.   BRITISH JOURNAL OF CANCER

Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity

(2009) Nielka P. van Erp et al.   JOURNAL OF CLINICAL ONCOLOGY